ClinicalTrials.gg
CompletedNCT00444587Updated Jun 21, 2016Results posted

A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.

A Phase 2 interventional study of Second line chemotherapy and trastuzumab [Herceptin] in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 30 sites in 8 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-21.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
111th of 366
114 · median 61
Started
2007
with 18 others
Phase 2
239 of 374
44 open now
Registered
92nd of 374
by date
Lead sponsor
31 of 374
Hoffmann-La Roche

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 111th largest by enrollment of the 366 interventional ones that give a count, is one of 19 that started in 2007, is one of 239 in phase 2, and was the 92nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This 2 arm study will compare the efficacy and safety of continuation or discontinuation of Herceptin treatment in combination with 2nd line chemotherapy, in patients with HER2 positive metastatic breast cancer whose condition has progressed on 1st line chemotherapy plus Herceptin. Patients will be randomized either to continue or discontinue Herceptin treatment (6mg/kg iv infusion every 3 weeks) while receiving second-line chemotherapy of the investigator's choice. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female patients, >= 18 years of age;
  • breast cancer;
  • overexpression (IHC 3+ and/or FISH positive);
  • disease progression during or after previous chemotherapy + Herceptin;
  • scheduled to receive 2nd line chemotherapy.

Exclusion criteria

Exclusion Criteria:

  • concurrent immunotherapy or hormonal therapy;
  • anthracyclines as part of previous chemotherapy or planned 2nd line chemotherapy;
  • cardiac toxicity during previous 1st line chemotherapy + Herceptin;
  • history of other within last 5 years.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    Trastuzumab + 2nd Line Chemotherapy

    Drug: Second line chemotherapy · Drug: trastuzumab [Herceptin]

  • Active comparator
    Only Chemotherapy

    Drug: Second line chemotherapy

Interventions

06

What researchers measure

Primary outcomes

  1. Median Time to Disease Progression

    Time to disease progression (TTP) in days was defined as the time from enrollment to objective disease progression (all categories other than objective disease progression was set to be censored including death before progression). Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion, or the appearance of new lesions. Tumor assessments were performed using computer tomography or magnetic resonance imaging. TTP as assessed by investigator, along with a recalculation done by computer algorithm is presented below. Median time was not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

    Time frame: Up to 5 years

Secondary outcomes

  1. Objective Response Rate

    Objective response rate (ORR) is defined as the percentage of participants with tumor shrinkage of a predefined amount. It is a combination of complete response (CR) and partial response (PR) and was assessed according to the RECIST criteria 1.0. Complete response refers to the disappearance of all target lesions and all non-target non-measurable lesions. Partial Response refers to an at least 30 percent decrease in the sum of longest diameter of target lesions, taking as reference the baseline sum longest diameter. Objective response rate was not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

    Time frame: Up to 5 years

  2. Clinical Benefit Rate

    Clinical benefit rate (CBR) was defined as the percentage of participants taking a benefit from the treatments. CBR includes 1) Complete response (CR): disappearance of all target lesions and all non-target non-measurable lesions 2) Partial response (PR) : \>=30% decrease in the sum of the longest diameter of target lesions and 3) Stable disease (SD): non-PR and non-progressive disease. It was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST 1.0) and assessed by CT or MRI by the investigator. CBR was also assessed by computer. Clinical benefit rate was not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

    Time frame: Up to 5 years

  3. Median Time to Treatment Failure

    Time to treatment failure is defined as a composite endpoint measuring time (number of days) from enrollment to discontinuation of treatment or change in treatment for any reason, including disease progression, treatment toxicity and death. Median time to treatment failure was not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

    Time frame: Up to 5 years

  4. Overall Survival

    Overall Survival is defined as the time (number of days) between enrollment and the date of death due to any cause. Overall survival was not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

    Time frame: Up to 5 years

  5. Number of Participants With Any Adverse Events and Serious Adverse Events

    An adverse event (AE) is any untoward medical occurrence in a participant who is administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.

    Time frame: Up to 5 years

  6. Biochemistry Safety Laboratory Parameters: Mean Serum Glutamic Oxaloacetic Transaminase, Serum Glutamic-pyruvic Transaminase and Alkali Phosphatase Levels

    Participants in the study were evaluated for the serum glutamic oxaloacetic transaminase (SGOT), serum glutamic-pyruvic transaminase (SGPT) and alkali phosphatase (ALP) at Visit 1 and final study assessments (Up to 5 years). Serum glutamic oxaloacetic transaminase, Serum glutamic-pyruvic transaminase and Alkali Phosphatase levels were not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

    Time frame: Visit 1 [Screening Period (6 weeks prior to enrollment)] and Final study Assessments (Up to 5 years)

  7. Biochemistry Safety Laboratory Parameters: Mean Total Bilirubin and Serum Creatinine Levels

    Participants in the study were evaluated for the total bilirubin and serum creatinine. Total Bilirubin and serum creatinine levels were not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

    Time frame: Visit 1 [Screening Period (6 weeks prior to enrollment)] and Final study Assessments (Up to 5 years)

  8. Biochemistry Safety Laboratory Parameters: Mean Albumin Levels

    Participants in the study were evaluated for the albumin at Visit 1 and Final study assessments. Albumin levels were not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

    Time frame: Visit 1 [Screening Period (6 weeks prior to enrollment)] and Final study assessments (Up to 5 years)

  9. Biochemistry Safety Laboratory Parameters: Mean Urea, Sodium and Potassium Levels

    Participants in the study were evaluated for the biochemical safety laboratory parameters urea, sodium and potassium. Urea, sodium and potassium levels were not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

    Time frame: Visit 1 [Screening Period (6 weeks prior to enrollment)] and Final study assessments (Up to 5 years)

  10. Hematology Safety Laboratory Parameters: Mean Hemoglobin Levels

    Participants in the study were evaluated for the Hemoglobin up to 5 years. Hemoglobin levels were not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

    Time frame: Visit 1 [Screening Period (6 weeks prior to enrollment)] and final study assessments (Up to 5 years)

  11. Hematology Safety Laboratory Parameters: Mean Total Leukocytes Counts

    Participants in the study were evaluated for the total leukocytes up to 5 years. Total leukocytes counts were not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

    Time frame: Visit 1 [Screening Period (6 weeks prior to enrollment)] and final study assessments (Up to 5 years)

  12. Hematology Safety Laboratory Parameters: Percent of Differential for Neutrophils, Basophils, Eosinophils, Lymphocytes and Monocytes Counts

    Participants in the study were evaluated for the Neutrophils, Basophils, Eosinophils, Lymphocytes and Monocytes at Visit 1 and final study assessments. Neutrophils, Basophils, Eosinophils, Lymphocytes and Monocytes counts were not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

    Time frame: Visit 1 [Screening Period (6 weeks prior to enrollment)] and final study assessments (Up to 5 years)

  13. Hematology Safety Laboratory Parameter: Mean Platelets Counts

    Participants in the study were evaluated for the platelets at Visit 1 and final study assessments. Platelet counts were not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

    Time frame: Visit 1 [Screening Period (6 weeks prior to enrollment)] and final study assessments (Up to 5 years)

  14. Mean Left Ventricular Ejection Fraction

    Left ventricular ejection fraction (LVEF) is a measure of the percent of blood ejected from the ventricle in one heartbeat. It is a measure of cardiac function and was assessed by echocardiogram or multigated angiogram at Visit 0 \[Screening period (6 weeks prior to enrollment)\] and final study assessments (Up to 5 years).

    Time frame: Visit 0 [Screening period (6 weeks prior to enrollment)] and final study assessments (Up to 5 years).

07

Results

Posted Jun 21, 2016

Participant flow

A total of 114 participants were enrolled in this study conducted from March 2007 to August 2011 at 30 centers in 8 countries.

Participant flow — Overall Study
MilestoneTrastuzumab + 2nd Line ChemotherapyOnly Chemotherapy
Started9316
Completed101
Not completed8315
Withdrew: Death21
Withdrew: Progression of the disease738
Withdrew: Refused treatment/did not cooperate41
Withdrew: Investigator decision30
Withdrew: Protocol violation10
Withdrew: Missing05

Outcome measures

PrimaryMedian Time to Disease Progression

Time to disease progression (TTP) in days was defined as the time from enrollment to objective disease progression (all categories other than objective disease progression was set to be censored including death before progression). Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion, or the appearance of new lesions. Tumor assessments were performed using computer tomography or magnetic resonance imaging. TTP as assessed by investigator, along with a recalculation done by computer algorithm is presented below. Median time was not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

Time frame:
Up to 5 years
Reported as:
Median · Days
Median Time to Disease Progression
DaysTrastuzumab + 2nd Line Chemotherapy
By Computer (n = 65)171 (136 to 322)
By Investigator (n = 73)171 (136 to 265)
SecondaryObjective Response Rate

Objective response rate (ORR) is defined as the percentage of participants with tumor shrinkage of a predefined amount. It is a combination of complete response (CR) and partial response (PR) and was assessed according to the RECIST criteria 1.0. Complete response refers to the disappearance of all target lesions and all non-target non-measurable lesions. Partial Response refers to an at least 30 percent decrease in the sum of longest diameter of target lesions, taking as reference the baseline sum longest diameter. Objective response rate was not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

Time frame:
Up to 5 years
Reported as:
Number · Percentage of participants
Objective Response Rate
Percentage of participantsTrastuzumab + 2nd Line Chemotherapy
By Investigator (n= 87)43.7 (33.1 to 54.8)
By computer (n=87)43.7 (33.1 to 54.8)
SecondaryClinical Benefit Rate

Clinical benefit rate (CBR) was defined as the percentage of participants taking a benefit from the treatments. CBR includes 1) Complete response (CR): disappearance of all target lesions and all non-target non-measurable lesions 2) Partial response (PR) : \>=30% decrease in the sum of the longest diameter of target lesions and 3) Stable disease (SD): non-PR and non-progressive disease. It was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST 1.0) and assessed by CT or MRI by the investigator. CBR was also assessed by computer. Clinical benefit rate was not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

Time frame:
Up to 5 years
Reported as:
Number · Percentage of participants
Clinical Benefit Rate
Percentage of participantsTrastuzumab + 2nd Line Chemotherapy
By Computer (n = 87)75.9 (65.5 to 84.4)
By Investigator (n = 87)72.4 (61.8 to 81.5)
SecondaryMedian Time to Treatment Failure

Time to treatment failure is defined as a composite endpoint measuring time (number of days) from enrollment to discontinuation of treatment or change in treatment for any reason, including disease progression, treatment toxicity and death. Median time to treatment failure was not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

Time frame:
Up to 5 years
Reported as:
Median · Days
Median Time to Treatment Failure
DaysTrastuzumab + 2nd Line Chemotherapy
Median Time to Treatment Failure154 (131 to 238)
SecondaryOverall Survival

Overall Survival is defined as the time (number of days) between enrollment and the date of death due to any cause. Overall survival was not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

Time frame:
Up to 5 years
Reported as:
Median · Days
Overall Survival
DaysTrastuzumab + 2nd Line Chemotherapy
Overall Survival717 (589 to 1057)
SecondaryNumber of Participants With Any Adverse Events and Serious Adverse Events

An adverse event (AE) is any untoward medical occurrence in a participant who is administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.

Time frame:
Up to 5 years
Reported as:
Number · Number of participants
Number of Participants With Any Adverse Events and Serious Adverse Events
Number of participantsTrastuzumab + 2nd Line ChemotherapyOnly Chemotherapy
Number of participants with any AE8410
Number of participants with any SAE202
SecondaryBiochemistry Safety Laboratory Parameters: Mean Serum Glutamic Oxaloacetic Transaminase, Serum Glutamic-pyruvic Transaminase and Alkali Phosphatase Levels

Participants in the study were evaluated for the serum glutamic oxaloacetic transaminase (SGOT), serum glutamic-pyruvic transaminase (SGPT) and alkali phosphatase (ALP) at Visit 1 and final study assessments (Up to 5 years). Serum glutamic oxaloacetic transaminase, Serum glutamic-pyruvic transaminase and Alkali Phosphatase levels were not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

Time frame:
Visit 1 [Screening Period (6 weeks prior to enrollment)] and Final study Assessments (Up to 5 years)
Reported as:
Mean · Units per liter
Biochemistry Safety Laboratory Parameters: Mean Serum Glutamic Oxaloacetic Transaminase, Serum Glutamic-pyruvic Transaminase and Alkali Phosphatase Levels
Units per literTrastuzumab + 2nd Line Chemotherapy
SGOT, Visit 1, (n = 93)31.46 ± 29.78
SGOT, Final study assessments, (n = 62)36.16 ± 34.91
SGPT, Visit 1, (n = 93)25.86 ± 20.55
SGPT, Final study assessments, (n = 61)28.19 ± 16.92
ALP, Visit 1, (n = 93)202.30 ± 149.98
ALP, Final study assessments, (n = 62)193.49 ± 148.11
SecondaryBiochemistry Safety Laboratory Parameters: Mean Total Bilirubin and Serum Creatinine Levels

Participants in the study were evaluated for the total bilirubin and serum creatinine. Total Bilirubin and serum creatinine levels were not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

Time frame:
Visit 1 [Screening Period (6 weeks prior to enrollment)] and Final study Assessments (Up to 5 years)
Reported as:
Mean · Micromole/liter
Biochemistry Safety Laboratory Parameters: Mean Total Bilirubin and Serum Creatinine Levels
Micromole/literTrastuzumab + 2nd Line Chemotherapy
Total bilirubin, Visit 1, (n = 93)13.50 ± 42.74
Total bilirubin, Final study assessments(n = 60)19.16 ± 36.77
Serum creatinine, Visit 1, (n = 92)81.18 ± 61.75
Serum creatinine,Final study assessment (n = 63)82.53 ± 70.86
SecondaryBiochemistry Safety Laboratory Parameters: Mean Albumin Levels

Participants in the study were evaluated for the albumin at Visit 1 and Final study assessments. Albumin levels were not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

Time frame:
Visit 1 [Screening Period (6 weeks prior to enrollment)] and Final study assessments (Up to 5 years)
Reported as:
Mean · gram per liter
Biochemistry Safety Laboratory Parameters: Mean Albumin Levels
gram per literTrastuzumab + 2nd Line Chemotherapy
Albumin, Visit 1, (n = 84)43.99 ± 3.29
Albumin, Final study assessments, (n = 54)41.07 ± 6.96
SecondaryBiochemistry Safety Laboratory Parameters: Mean Urea, Sodium and Potassium Levels

Participants in the study were evaluated for the biochemical safety laboratory parameters urea, sodium and potassium. Urea, sodium and potassium levels were not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

Time frame:
Visit 1 [Screening Period (6 weeks prior to enrollment)] and Final study assessments (Up to 5 years)
Reported as:
Mean · Millimole per liter
Biochemistry Safety Laboratory Parameters: Mean Urea, Sodium and Potassium Levels
Millimole per literTrastuzumab + 2nd Line Chemotherapy
Urea, Visit 1, (n = 92)6.33 ± 3.07
Urea, Final study assessments, (n = 63)6.92 ± 4.93
Sodium, Visit 1, (n = 92)140.58 ± 3.34
Sodium, Final study assessments, (n = 61)139.16 ± 3.71
Potassium, Visit 1, (n = 91)4.40 ± 0.45
Potassium, Final study assessments, (n = 61)4.22 ± 0.40
SecondaryHematology Safety Laboratory Parameters: Mean Hemoglobin Levels

Participants in the study were evaluated for the Hemoglobin up to 5 years. Hemoglobin levels were not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

Time frame:
Visit 1 [Screening Period (6 weeks prior to enrollment)] and final study assessments (Up to 5 years)
Reported as:
Mean · grams per deciliter
Hematology Safety Laboratory Parameters: Mean Hemoglobin Levels
grams per deciliterTrastuzumab + 2nd Line Chemotherapy
Hemoglobin, Visit 1, (n = 93)12.67 ± 2.03
Hemoglobin, Final study assessments, (n = 67)11.00 ± 3.57
SecondaryHematology Safety Laboratory Parameters: Mean Total Leukocytes Counts

Participants in the study were evaluated for the total leukocytes up to 5 years. Total leukocytes counts were not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

Time frame:
Visit 1 [Screening Period (6 weeks prior to enrollment)] and final study assessments (Up to 5 years)
Reported as:
Mean · 10^9 leukocytes/L
Hematology Safety Laboratory Parameters: Mean Total Leukocytes Counts
10^9 leukocytes/LTrastuzumab + 2nd Line Chemotherapy
Total Leukocytes, Visit 1, (n = 92)8.00 ± 8.60
Total Leukocytes, Final study assessment (n =67)7.53 ± 6.88
SecondaryHematology Safety Laboratory Parameters: Percent of Differential for Neutrophils, Basophils, Eosinophils, Lymphocytes and Monocytes Counts

Participants in the study were evaluated for the Neutrophils, Basophils, Eosinophils, Lymphocytes and Monocytes at Visit 1 and final study assessments. Neutrophils, Basophils, Eosinophils, Lymphocytes and Monocytes counts were not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

Time frame:
Visit 1 [Screening Period (6 weeks prior to enrollment)] and final study assessments (Up to 5 years)
Reported as:
Mean · percent of differential
Hematology Safety Laboratory Parameters: Percent of Differential for Neutrophils, Basophils, Eosinophils, Lymphocytes and Monocytes Counts
percent of differentialTrastuzumab + 2nd Line Chemotherapy
Neutrophils, Visit 1, (n = 93)64.89 ± 10.66
Neutrophils, Final study assessments, (n = 64)62.22 ± 14.80
Basophils, Visit 1, (n = 86)0.38 ± 0.33
Basophils, Final study assessments, (n = 59)1.28 ± 6.34
Eosinophils, Visit 1, (n = 88)2.36 ± 2.15
Eosinophils, Final study assessments, (n = 61)2.50 ± 3.56
Lymphocytes, Visit 1, (n = 93)26.34 ± 9.37
Lymphocytes, Final study assessments, (n = 64)26.48 ± 12.85
Monocytes, Visit 1, (n = 89)5.92 ± 2.22
Monocytes, Final study assessments, (n = 59)7.25 ± 3.56
SecondaryHematology Safety Laboratory Parameter: Mean Platelets Counts

Participants in the study were evaluated for the platelets at Visit 1 and final study assessments. Platelet counts were not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.

Time frame:
Visit 1 [Screening Period (6 weeks prior to enrollment)] and final study assessments (Up to 5 years)
Reported as:
Mean · Number of cells x 10^9/L
Hematology Safety Laboratory Parameter: Mean Platelets Counts
Number of cells x 10^9/LTrastuzumab + 2nd Line Chemotherapy
Platelets, Visit 1, (n = 93)263.14 ± 63.91
Platelets, Final study assessments, (n = 67)256.64 ± 78.64
SecondaryMean Left Ventricular Ejection Fraction

Left ventricular ejection fraction (LVEF) is a measure of the percent of blood ejected from the ventricle in one heartbeat. It is a measure of cardiac function and was assessed by echocardiogram or multigated angiogram at Visit 0 \[Screening period (6 weeks prior to enrollment)\] and final study assessments (Up to 5 years).

Time frame:
Visit 0 [Screening period (6 weeks prior to enrollment)] and final study assessments (Up to 5 years).
Reported as:
Mean · percent of blood pumped from LV chamber]
Mean Left Ventricular Ejection Fraction
percent of blood pumped from LV chamber]Trastuzumab + 2nd Line ChemotherapyOnly Chemotherapy
Visit 0 (n = 92, 16)63.3 ± 6.862.6 ± 6.9
Final study assessment (n= 53, 5)61.2 ± 7.468.6 ± 5.9

Adverse events

Collected over Up to 5 years. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab + 2nd Line Chemotherapy—20/93 (21.5%)81/93 (87.1%)
Only Chemotherapy—2/16 (12.5%)9/16 (56.3%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventTrastuzumab + 2nd Line ChemotherapyOnly Chemotherapy
Angina pectorisCardiac disorders0/931/16
DeathGeneral disorders0/931/16
PneumoniaInfections and infestations5/930/16
DiarrhoeaGastrointestinal disorders3/930/16
LeukopeniaBlood and lymphatic system disorders2/930/16
Cardiopulmonary failureCardiac disorders2/930/16
GranulocytosisBlood and lymphatic system disorders1/930/16
Atrial fibrillationCardiac disorders1/930/16
Retinal detachmentEye disorders1/930/16
NauseaGastrointestinal disorders1/930/16
Most frequent other events
Showing 10 of 108
Most frequent other events
EventTrastuzumab + 2nd Line ChemotherapyOnly Chemotherapy
NeutropeniaBlood and lymphatic system disorders80/931/16
LeukopeniaBlood and lymphatic system disorders76/933/16
NauseaGastrointestinal disorders53/930/16
DiarrhoeaGastrointestinal disorders52/931/16
FatigueGeneral disorders30/937/16
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders37/934/16
AnemiaBlood and lymphatic system disorders25/935/16
Oedema peripheralGeneral disorders8/934/16
VomitingGastrointestinal disorders21/931/16
HypertensionVascular disorders19/931/16

Baseline characteristics

The Safety Population included all participants who entered the trial and received at least one dose of trial medication.

Age, Continuous
Age, Continuous(years)Trastuzumab + 2nd Line ChemotherapyOnly ChemotherapyTotal
Mean55.4 ± 12.856.3 ± 10.255.5 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab + 2nd Line ChemotherapyOnly ChemotherapyTotal
Female9316109
Male000
08

Study locations

30 sites
  • Sofia, 1527, Bulgaria
  • Tallinn, 13419, Estonia
  • Budapest, 1082, Hungary
  • Budapest, 1115, Hungary
  • Budapest, 1122, Hungary
  • Budapest, 1125, Hungary
  • Budapest, 1135, Hungary
  • Budapest, 1145, Hungary
  • Debrecen, 4032, Hungary
  • Győr, 9023, Hungary
  • Gyula, 5700, Hungary
  • Nyíregyháza, 4400, Hungary
  • Szeged, 6725, Hungary
  • Székesfehérvár, 8000, Hungary
  • Szombathely, 9700, Hungary
  • Haifa, 31096, Israel
  • Holon, 58100, Israel
  • Petah Tikva, 49100, Israel
  • Ramat Gan, 52621, Israel
  • Rehovot, 76100, Israel
  • Safed, 13110, Israel
  • Tel Aviv, 6423906, Israel
  • Ẕerifin, 70300, Israel
  • Kaunas, 50009, Lithuania
  • Vilnius, 08660, Lithuania
  • Skopje, 1000, North Macedonia
  • Bratislava, 812 50, Slovakia
  • Košice, 041 90, Slovakia
  • Adana, 01330, Turkey (Türkiye)
  • Ankara, 06590, Turkey (Türkiye)
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 4 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2007
First posted
Mar 8, 2007
Start
Mar 2007
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results first posted
Jun 21, 2016
Last update
Jun 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00444587
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 8, 2007
Start date
Mar 2007
Primary completion
Aug 2011
Completion
Aug 2011
Results posted
Jun 21, 2016
Last update
Jun 21, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion